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Sumoylation is a post-translational modification by which small ubiquitin-like modifiers (SUMO) are covalently conjugated to target proteins.
This reversible pathway provides a rapid and efficient way to modulate the subcellular localization, activity and stability of a wide variety of
substrates. Similar to its well-known cousin ubiquitin, SUMO co-localize with the neuronal inclusions associated with several neurodegenerative
diseases, including multiple system atrophy, Huntington's disease and other related polyglutamine disorders. The identification of huntingtin,
ataxin-1, tau and α-synuclein as SUMO substrates further supports the involvement of sumoylation in the pathogenesis of this family of
neurological diseases. In addition to direct targeting of these constituent proteins, sumoylation also impacts other disease pathways such as
oxidative stress, protein aggregation and proteasome-mediated degradation. This review highlights the recent advances in understanding the
contributions of SUMO to neurodegeneration and the underlying pathogenic mechanisms of these diseases.
© 2007 Elsevier B.V. All rights reserved.Keywords: SUMO; Neurodegenerative diseases; Proteasome; Ubiquitin; Neuronal inclusions1. Introduction
Post-translational modifications are rapid, efficient and
reversible means of regulating protein stability, localization,
interactions and function. These include chemical modifications
such as phosphorylation or methylation as well the attachment
of ubiquitin or the several ubiquitin-like proteins which have
been identified in eukaryotic cells [1]. These complex bio-
chemical pathways are tightly regulated and control a wide
variety of unique cellular processes. Perturbations within these
modification systems have been shown to contribute to the
etiology of various cancers, inflammatory diseases and neuro-
degenerative processes.
Small ubiquitin-like modifiers (SUMO) are covalently
conjugated to target proteins and modulate a growing number
of cellular pathways. Similar to ubiquitin, SUMO are linked
directly to the amino sidechains of lysine residues and, in some
instances, both modifiers target the same substrate. This
suggests a dynamic interplay between the related ubiquitination⁎ Corresponding author. Tel.: +1 416 978 0102; fax: +1 416 978 1878.
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doi:10.1016/j.bbamcr.2007.03.017and sumoylation pathways. Neuronal inclusions are frequently
immunoreactive for ubiquitin, proteasome components and, as
recently demonstrated, SUMO proteins. In support of these
observations, the constituent neuronal proteins within these
disease-specific aggregates are targets for SUMO conjugation.
This review summarizes the recent findings related to
sumoylation in neurodegeneration and highlights their involve-
ment in the pathogenesis of neurological diseases.
2. The SUMO conjugation pathway
Despite their primary sequence divergence, ubiquitin and
SUMO proteins exhibit considerable structural overlap and
share the biochemical mechanisms of substrate conjugation. In
humans, three major SUMO isoforms are expressed and are
evolutionarily conserved as shown, for example, by the
sequence similarity (∼56%) of SUMO1 to its yeast homolog
Smt3 (Fig. 1). SUMO1 (previously known as sentrin, Ubl1,
GMP1, PIC1 and Smt3c) displays ∼50% sequence similarity
with the highly homologous SUMO2 (also known as sentrin3
and Smt3a) and SUMO3 (also known as sentrin2 and Smt3b)
paralogs. The sequence identity shared by SUMO2 and
Fig. 1. Comparison of yeast and human SUMO isoforms and ubiquitin. Sequence alignment (CLUSTALW) of human SUMO1, SUMO2, SUMO3 (top panel).
SUMO2 and SUMO3 share ∼95% sequence homology and ∼50% with SUMO1. SUMO1 is ∼20% similar to human ubiquitin and shares ∼56% sequence identity
with the yeast homolog Smt3 (bottom panel). The diglycine (GG) conjugation residues (red) as well as the sites for polySUMO chain attachments (blue) are also
indicated.
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antibodies which can distinguish between these two isoforms.1
Therefore examining SUMO2/3 subcellular localization and
expression at the protein level has been limited. All SUMO
isoforms display cell type-specific expression levels as well as
unique, although not exclusive, subcellular localizations.
SUMO1 is mainly found at the nuclear membrane while
SUMO2 and SUMO3 are predominantly localized in the
cytoplasm and nuclear bodies, respectively [2].
A fourth isoform, SUMO4, has been identified and is highly
homologous to SUMO3. Its messenger has been shown to be
mainly expressed in kidney cells [3]. However, the intronless
gene has been suggested to be one of the numerous SUMO3
pseudogenes [2], as the expression of the endogenous protein
has yet to be demonstrated. Further studies are required to
resolve this issue and establish the functional role of SUMO4.
Similar to ubiquitin and other ubiquitin-like proteins, SUMO
isoforms are expressed as precursor proteins. In order to expose
the C-terminal diglycine motif required for conjugation to
targets, SUMO undergoes a maturation process during which
the cleavage of the C-terminal extension is carried out by one of
the specific SUMO proteases (for review, see [4]) (Fig. 2). The1 The conflicting designation of SUMO2 and SUMO3 in the National Center
for Biotechnology Information database and a number of publications has led to
confusion on nomenclature. The present review uses the original notation, as
previously described [45].resulting mature SUMO protein enters a multi-step enzymatic
pathway that is comparable to but distinct from ubiquitination.
The sumoylation reaction is initiated by ATP-dependent
formation of a thioester bond between the exposed C-terminal
glycine of SUMO and an internal cysteine in the SUMO
activating (E1) enzyme, a heterodimer composed of SAE1 and
SAE2 subunits [5]. Through a transesterification reaction,
activated SUMO is subsequently transferred to the catalytic
cysteine of the unique SUMO conjugating (E2) enzyme Ubc9
[6].
In contrast to ubiquitin conjugating enzymes, Ubc9 has the
ability to recognize target proteins directly and catalyze the
formation of an isopeptide bond between the C-terminal glycine
of SUMO and the ε-amino group of a target lysine [7]. Analysis
of SUMO substrates has demonstrated that a majority of target
lysines (K) are contained within a SUMO consensus motif
defined by ΨKX(E/D). The Ψ corresponds to a hydrophobic
residue, X is any amino acid and E/D is either a glutamate or
aspartate residue [8]. This SUMO motif is recognized by the
conjugating enzyme Ubc9 [9]. SUMO2 and SUMO3 contain
this recognition motif in their N-terminal domains, which
allows them to form polySUMO chains [10]. However, not all
proteins containing SUMO consensus sequences are sumoy-
lated. Conversely, substrates lacking the SUMO motif can
effectively be modified by SUMO, which is exemplified by the
ability of SUMO1 to also form polySUMO chains [11–13]. A
number of studies have shown that SUMO1 and SUMO2/
Fig. 2. The SUMO conjugation pathway. SUMO is expressed as a precursor protein and processed by a SUMO-specific protease (SENP) to expose the C-terminal
diglycine motif (maturation). Mature SUMO is activated in an ATP-dependent manner by the SUMO activating enzyme (E1) SAE1/SAE2 and is transferred through a
transesterification process to the unique SUMO conjugating enzyme (E2) Ubc9. SUMO is next conjugated to the target lysine of a substrate, defined by the consensus
motif ΨKXE/D. Conjugation, in some instances, is facilitated by a SUMO E3 ligase. The sumoylation pathway is reversible as specific proteases can remove and
recycle SUMO moieties from modified substrates.
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that the two subfamilies are functionally distinct [19].
SUMO (E3) ligases increase the overall efficiency of
sumoylation, ensure substrate specificity to some extent and
are thought to facilitate SUMO modification of targets lacking
the consensus motif. In humans, members of the PIAS family
[20,21], RanBP2 [22], the polycomb chromatin-modifying
complex component Pc2 [23], Topors [24] and TRAF7 [25]
have been shown to possess SUMO ligase activity. The large
number of SUMO substrates as compared to the limited number
of enzymes suggests that additional SUMO E3 ligases and
cofactors/regulators likely remain to be identified.
As with many other post-translational modifications,
sumoylation is highly dynamic and reversible. The same
proteases involved in the maturation of the precursor proteins
are also responsible for the removal and recycling of SUMOs
from their substrates. Although the conjugation and deconjuga-
tion pathways are biochemically well defined, recent investiga-
tions continue to shed light on how these are regulated at both
the substrate and enzyme levels (for review, see [26]). For
example, acetylation or ubiquitination of target lysines creates a
steric regulator of conjugation while substrate phosphorylation
has been shown to alternatively stimulate and suppress
sumoylation (for review, [26]). A proline-directed phosphory-
lation-dependent sumoylation motif (PDSM) has been identi-
fied in transcriptional factors which regulates sumoylation [27].
This motif is a variation of the sumoylation consensus sequence
and is defined by ΨKXEXXSP, where S and P correspond to
serine and proline residues. Reactive oxygen species (ROS)
have also been identified as controlling factors for the regulation
of SUMO E1 and E2 [28].
Studies have also revealed details on the molecular basis by
which cells discriminate between different SUMO isoforms. In
addition to their specific subcellular localizations [4], SUMOproteases have differential abilities to catalyze the maturation of
SUMO precursors (C-terminal hydrolase activity) or the
desumoylation reaction of SUMO-modified substrates (isopep-
tidase activity) [29]. SUMO proteases also display a preference
towards certain SUMO isoforms [29–33]. This selectivity is
mediated by the surface charge complementarity between the
protease and the C-terminal domain of SUMO, which is unique
to each isoform [31].
A number of proteins are conjugated by both SUMO and
ubiquitin using identical lysine residues, which has raised the
possibility that sumoylation may act as an antagonist of
proteasome-mediated degradation. The competition between
both conjugation pathways could represent a means of
modulating substrate stability. However, evidence to date
indicates that the communication between sumoylation and
ubiquitination is much more complex than simple competition
for common target lysines or substrate proteins (for review, see
[34]). For example, sumoylation of the ubiquitin conjugating
enzyme E2-25K has been shown to inhibit its activity [35].
Conversely, SUMO E1 and E2 enzymes are downregulated by
the proteasome in the presence of the adenoviral protein Gam1
[36]. However, the relationship between SUMO and ubiquitin–
proteasome pathways is not only antagonistic. Both modifica-
tion pathways have been shown to converge in the case of
nuclear promyelocytic leukaemia (PML)-bodies, also known as
nuclear bodies (NB) [13,37]. These subnuclear bodies are
thought to integrate both sumoylation and proteasome-mediated
degradation systems and proteasome inhibitors stimulate the
colocalization of both modifiers at these sites [37].
In terms of their functional effects, SUMO modification
modulates transcriptional activity of a large number of
transcription factors, including p53 [38] and the androgen
receptor [39], as well as the activity of regulators such as IκBα
[40]. Disruption of the SUMO pathway in human cells, for
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[32]. Mutation of its yeast homolog, Ulp1, results in G2/M cell
cycle arrest [41]. These implicate sumoylation in the cell cycle
progression. SUMO also participates to the maintenance of
genome integrity, for example by modifying proteins involved
in DNA repair, such as PCNA [42]. All these functions are
consistent with many known SUMO substrates which are
primarily located within the nucleus. Although sumoylation has
originally been seen as a nuclear process, proteomic studies
have shown that a significant portion of transmembrane, such as
Glut1, Glut4 and ErbB3, and cytoplasmic proteins associated
with different organelles, including the endoplasmic reticulum
and mitochondria, are also subject to SUMO modification
[43,44]. This rapidly growing catalogue of SUMO substrates
encompasses a wide selection of proteins which have not yet
been fully explored but suggests that SUMO conjugation may
contribute to a broad range of cellular pathways [15,44].
Consequently, in addition to its activities within the nucleus,
sumoylation may also affect subcellular transport, protein
stability, signal transduction pathways and the formation of
protein complexes (for review, see [45]).
An important emerging aspect in SUMO biology is their
ability to regulate biochemical pathways independent of their
conjugation to target substrates. Non-covalent interaction of
SUMO and Ubc9 with dynamin downregulates dynamin-
mediated endocytosis of transferrin [46]. The Parkinson's
disease-related protein parkin also interacts non-covalently
with SUMO, which results in its nuclear localization and
autoubiquitination [47]. Other physiological processes invol-
ving thymine DNA glycosylase [48] and the androgen receptor
[49] are also mediated by non-covalent association with SUMO.
Generic SUMO-binding motifs (SBM) have been identified and
consist of a hydrophobic core which is adjacent to a series of
acidic residues and contains potential phosphorylation sites
[50–53]. Structural studies have demonstrated that, unlike the
helical ubiquitin-binding motifs, the SBM are conformationally
flexible and are located between α-helical and β-strand
structures [53]. The functional consequences of these interac-
tions are illustrated by the fact that non-covalent association of
PML with sumoylated proteins constitutes the nucleating event
for the formation of nuclear bodies [54,55]. These observations
indicate that, even in the absence of direct conjugation, binding
of SUMO monomers with SBM-containing proteins can have
significant effects on partitioning of proteins within cells and
the assembly of protein complexes.
3. Sumoylation and neurodegeneration
Neurodegenerative disorders are typically characterized by
progressive and extensive neuronal loss in specific populations
of neurons and brain areas which lead to the observed clinical
manifestations. One of the common features of these diseases is
the aggregation and accumulation of misfolded proteins which
is considered to be a key event in the pathogenic process. Each
disorder has a unique histopathological signature which is
defined by the constituent proteins within the inclusions as well
as the distribution and cellular location of the deposits. Thecontribution of these aggregated proteins to neuronal death has
been debated and it has been proposed that the nuclear
deposition of huntingtin may be neuroprotective [56,57]. In
contrast, soluble oligomeric forms of the amyloid-β (Aβ)
peptide found in senile plaques are thought to be the primary
cytotoxic species in Alzheimer's disease [58,59].
The involvement of proteasome-mediated degradation in the
family of neurodegenerative diseases is inferred by the presence
of ubiquitin and related protein components in inclusion bodies
(for review, see [60]). This is further supported by genetic
linkage of mutations in the ubiquitin ligase parkin [61] and the
ubiquitin carboxy-terminal hydrolase UCHL1 [62] to familial
Parkinson's disease. Similarly, SUMO proteins have also been
detected within inclusions in various neurodegenerative dis-
eases such as multiple system atrophy, Huntington's disease and
other related polyglutamine disorders. In addition, several
proteins specifically implicated in these neurological diseases
have been identified as SUMO targets. Given the pleiotropic
roles of SUMO modification on cellular processes as well as its
relationship with the ubiquitin pathway, there are a number of
possible mechanisms by which sumoylation can contribute to
the underlying neurodegenerative processes.
4. SUMO and polyglutamine diseases
Polyglutamine (polyQ) diseases are neurodegenerative
disorders that include Huntington's disease (HD), spinal and
bulbar muscular atrophy (SBMA), dentatorubral-pallidoluysian
atrophy (DRPLA) and a collection of spinocerebellar ataxias
(SCA-1, -2, -3, -6, -7, and -17) (for review, see [63]). These
neurological disorders are associated with the genomic expan-
sion of a CAG triplet repeat in the disease-specific genes. The
resulting proteins exhibit an abnormal extension of glutamine
residues to the polypeptide chain that can range from 35 to over
300 pathogenic repeats. The isolated polyQ stretch can be toxic,
but it is in the context of the full length protein that neuronal
death occurs. Although the mutant proteins can undergo
conformational changes that might interfere with their active
domains, clinical data and transgenic animal models support a
toxic gain-of-function of the polyQ proteins [64,65]. This
family of polyQ diseases have unique clinical and neuropatho-
logical characteristics but they all share the formation of
cytoplasmic and/or intranuclear protein inclusions in selective
populations of neurons. It is unclear if these aggregates
contribute to neuronal dysfunction or possibly represent a
protective mechanism, although some recent models suggest an
inverse correlation between accumulation of aggregates and
neuronal loss [56,57,66].
Molecular chaperones and proteasome subunits have been
detected within polyQ-aggregates and may represent a cellular
attempt to recruit defence mechanisms against protein misfold-
ing and aggregation or possibly the failure of the degradation
pathway. The involvement of the proteasome is supported by
immunohistochemical studies showing that the neuronal
inclusions are highly ubiquitin-positive. This is equally the
case for SUMO1 where enhanced immunoreactivity in affected
neurons of DRPLA, SCA-1, Machado–Joseph disease (MJD,
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been reported [67]. In addition, colocalization of SUMO and
polyQ protein aggregates has been demonstrated in histological
studies of individuals with DRPLA as well as for cellular
models of atrophin-1 inclusion bodies [68]. SUMO1 immunos-
taining has been demonstrated in selected nuclear aggregates
associated with MJD, although this does not always overlap
with ataxin-3 and is often located in different populations of
inclusions [69]. In contrast, neuronal models of huntingtin (Htt)
deposition indicated an association with SUMO1 [70]. Similar
co-localization of SUMO1 with both wildtype and mutant
ataxin-1 has been observed in SCA1 [71]. These studies
cumulatively demonstrate the presence of SUMO in neuronal
inclusions in a variety of polyQ disorders and suggest a
potential role for the ubiquitin-like protein in polyQ pathogen-
esis. While these association studies provide largely circum-
stantial evidence for the contribution of sumoylation in
neurodegeneration, support for this concept is provided by a
number of additional investigations.
The mutant protein involved in SBMA is a pathogenic polyQ
fragment of the androgen receptor (AR) which has been
modelled inDrosophila. This results in nuclear and cytoplasmic
aggregates as well as progressive neurodegeneration [72].
Expression of a catalytic-deficient C175S mutant form of the
SUMO activating enzyme (E1) subunit Uba2 (equivalent to the
human SAE2) greatly enhanced degeneration in this model.
Similar observations have been made in an MJD model using a
disease-related ataxin-3, which suggests that downregulation of
SUMO modification is detrimental to cells. This may also
involve overlapping functions of SUMO and the ubiquitin–
proteasome system, which has also been implicated in these
processes. For example, the SUMO E1 C175S degenerativeFig. 3. SUMO affects polyglutamine toxicity. (A) Sumoylation can directly alter
Alternatively, SUMO can promote the sequestration of transcription factors/regula
modulate nucleocytoplasmic transport, as exemplified by ataxin-1. Changes in subce
inclusions (4). (C) SUMO can antagonize the proteasome-mediated degradation of the
other proteins, and the formation of inclusions. Ultimately, these detrimental effectsphenotype is similar to that induced by the expression of a
dominant-negative form of Hsp70 or an inactive proteasome β-
subunit mutant [72]. In contrast to the mutant proteasome,
Hsp70 was unable to rescue the SUMO E1 mutant-induced
degeneration. This is consistent with the proposal that
sumoylation contributes to more than protein aggregation and/
or degradation and may be involved in other SUMO-modulated
cellular pathways (Fig. 3). This could include indirect events
involved in cell death such as SUMO1 modification of caspases
[73–75] or have a more direct impact on protein misfolding and
aggregation processes.
Direct links to sumoylation of disease-related proteins also
support the role in neurodegeneration, potentially by mediating
changes in protein solubility or levels of toxic soluble
oligomers and decreased cell survival (Fig. 3). In a neuronal
model of DRPLA, co-expression of wildtype SUMO1 with
polyQ-atrophin-1 significantly accelerated the formation of
nuclear aggregates and promoted apoptosis [68]. One proposed
explanation for this effect is SUMO disruption of or
competition with proteasome-mediated degradation of aggre-
gated mutant atrophin-1. An alternate possibility is the mis-
trafficking and/or sequestration of SUMO-modified proteins
that promoted their accumulation within the nucleus. With the
ability of SUMO to regulate protein–protein interactions via
non-covalent binding motifs [50–53], the recruitment of
SUMO monomers or sumoylated substrates into inclusions
could further exacerbate the sequestration of cellular compo-
nents that are critical for neuronal survival. Conversely, co-
expression of SUMO1 lacking the C-terminal diglycine motif
required to linkage reduced, but did not abolish, the accumu-
lation of polyQ-atrophin-1 aggregates. Expression of the
conjugation-deficient SUMO promoted cell survival, astranscriptional activity of the mutant polyQ protein, such as Huntingtin (1).
tors and indirectly affect gene transcription (2). (B) SUMO modification can
llular localization can potentially affect transcription (3) and/or the formation of
mutant polyQ protein, leading to its accumulation, possibly the sequestration of
lead to neuronal loss and the onset of clinical symptoms.
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of wild-type SUMO1.
SUMO1 has been implicated in protein aggregation and
formation of inclusions but, until recently, it was unclear if the
constituent proteins were targets for sumoylation. For example,
wild-type androgen receptor (AR) is a known SUMO1 substrate
and sumoylation negatively regulates its transcriptional activity
[39]. However, it is not known if or to what extent the
pathogenic polyQ-AR is sumoylated and how sumoylation
might contribute to the development of SBMA. One of the first
polyQ-related SUMO substrates identified was a pathogenic
fragment of huntingtin (Htt) [70] (Table 1). Expression of a
permanent, non-hydrolyzable Htt-SUMO conjugate in a
neuronal cell line resulted in a more stable protein and increased
Htt-mediated transcriptional repression. This also resulted in
decreased formation of inclusions and potentially an increase in
the levels of toxic oligomers. The SUMO1 conjugation sites are
located within the N-terminal domain of the Htt peptide and
overlap with the lysine residues targeted by ubiquitin, which
may lead to competition between the two modifiers.
The relative contribution of ubiquitin and SUMO to
pathogenesis has been investigated in Drosophila models.
Expression of mutant Htt led to progressive degeneration,
which was reduced in flies heterozygous for SUMO and
modestly worsened in flies with genetically reduced ubiquitina-
tion. Furthermore, expression of a mutant Htt in which the
conjugation lysines were mutated substantially decreased
degeneration. This indicated that the availability of the target
lysines is essential for degeneration and that sumoylation at
these sites results in a more significant pathological response as
compared to the slight amelioration associated with ubiquitina-
tion. However, a coordinated sequential action between SUMO
and ubiquitin on Htt, as previously reported for NEMO [76],
remains a possibility but this has yet to be explored. The overall
dynamic and cooperation between both modification systems
may be more important than the conjugation of individual
modifier separately.
SUMO-mediated changes in protein transport into the
nucleus may also be a contributory factor in these diseases.
Mutant ataxin-1 accumulates in SCA1 and is covalently
modified by SUMO1 (Table 1) via at least five different target
lysines [71]. An increase in the length of the polyQ stretch
negatively regulates ataxin-1 sumoylation. The SUMO mod-
ification is modulated by phosphorylation and is also dependent
upon translocation mediated by a nuclear localization signalTable 1
Pathogenic SUMO substrates in neurodegenerative diseases
SUMO substrate Pathology Reference
Huntingtin Huntington's disease [70]







DJ-1 Parkinson's disease [96]
SOD1 Amyotrophic lateral sclerosis [108](NLS). This study suggested that SUMO modification may
control the nuclear import/export efficiency of ataxin-1 or
regulate its trafficking within the nucleus. This role for SUMO
is in accordance with the findings for sumoylated Htt [70] and
additional evidence regarding sumoylation and nuclear translo-
cation [17]. In the case of Htt, its N-terminal domain is
responsible for cytoplasmic targeting proteins and therefore
SUMO conjugation within this domain could mask a cytoplas-
mic retention signal and promote the nuclear localization. This
potential mechanism could provide an explanation for the
SUMO-mediated increase in Htt transcriptional repression.
The possibility that polyQ disorders are pathologies of
protein transport or “transportopathies” has been proposed [77],
which may involve contributions from the SUMO pathway. A
consequence of this shuttling defect could be interference with
gene transcription, which is a common feature of these
disorders. This provides an additional link as sumoylation is a
well-defined regulator of transcription (for review see [78]) and
several of polyQ-related proteins function as transcriptional
regulators (see review [63]). A direct pathological implication
of SUMO in polyQ diseases is suggested by the SUMO-
mediated increase in Htt transcriptional repression [70]. Many
of the polyQ-interacting partners recruited into neuronal
inclusions, including the nuclear bodies protein PML [79,80],
p53 [81] and c-jun [79] are also SUMO substrates. Sumoylation
may therefore modulate their ability to interact with polyQ
mutant proteins and/or be recruited into transcriptional com-
plexes. A recent report demonstrated the role of SUMO in
synapses through the regulation of the transcription factor
MEF2A [82]. It is therefore plausible that SUMO could be
involved in transcriptional dysregulation in neurodegenerative
diseases.
5. Neuronal intranuclear inclusion disease
Neuronal intranuclear inclusion disease (NIID) is a rare
neurodegenerative disorder characterized by the presence of
widespread eosinophilic intranuclear inclusions [83]. NIID can
present as juvenile and adult-onset cases and the majority of
these are sporadic but examples of familial occurrence have
been reported [84]. The predominant neurological symptoms in
younger cases are ataxia and movement disorders, whereas
adult cases are commonly characterized by dementia. This
heterogeneity of the clinical features suggests that the two age
groups may be pathologically distinct [85]. While the
histopathology is comparable to polyQ-related disorders, there
is no evidence for CAG expansions in NIID. Interestingly, the
inclusions are only weakly labelled with a polyQ repeat-specific
antibody [69,86], but ataxin-1 and ataxin-3 are detected within
the NIID aggregates [87].
Extensive SUMO1 immunostaining has been observed in
nuclear inclusions in three cases of familial NIID and
immunoelectron microscopy revealed diffuse SUMO1 labelling
of the fibrillar inclusions [69]. Ubiquitin and SUMO1
immunoreactivities completely overlapped and revealed a
similar density and brain distribution within the inclusions.
SUMO1 staining in NIID inclusions is also more intense and
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reported for polyQ aggregates [67–69]. This suggests that
inclusions in NIID significantly differ from polyQ diseases.
Robust SUMO1 immunostaining which was more intense than
that seen for ubiquitin has also been observed in intranuclear
inclusions associated with juvenile NIID [85]. SUMO1 staining
in neuronal intranuclear inclusions has been confirmed in both
familial and sporadic NIID cases [80]. Co-localization of
SUMO1 with neuronal inclusions in these various groups of
NIID cases suggests a potential role for sumoylation in the
disease pathogenesis.
The identity of the SUMO targets within NIID aggregates
has yet to be determined but the transcription co-repressor,
histone deacetylase HDAC4, is associated with nuclear
inclusions and represents a potential candidate substrate [80].
Another possibility is that the aggregates in NIID arise from
promyelocytic leukaemia (PML) nuclear bodies, which pro-
vides a further link to sumoylation. PML nuclear bodies (NB)
are subnuclear structures that participate in various nuclear
processes including intranuclear protein degradation mediated
by the proteasome [88,89]. Evidence suggests the convergence
and integration of both ubiquitin and sumoylation pathways in
NBs [37]. It has been shown that neuronal intranuclear
inclusions in sporadic and familial NIID cases contained
PML along with SUMO1 and ubiquitin [80]. This colocaliza-
tion is also found in supraoptic neurons [13] and familial cases
of tau-negative/ubiquitin-positive frontotemporal dementia
[90]. In NIID, a ring-like PML immunoreactivity characteristic
of normal NBs was observed specifically in small inclusions,
whereas large aggregates completely lacked or displayed
granular PML staining. It is possible that, as a result of
impairments in sumoylation or ubiquitination, proteins nor-
mally destined for degradation accumulate in NBs and form
small inclusions. However, in one study, PML staining has not
been observed in juvenile [85] and familial forms of NIID [69]
which suggests that this may represent a secondary event in the
formation of the inclusions. However, this may be due to a
different time course for these cases and the potential for
disruption of normal NB function in the sporadic cases cannot
be excluded. The evidence to date indicates that it is con-
ceivable that a defect in SUMO- and/or proteasome-mediated
protein degradation may promote formation of NIID inclu-
sions, disrupt normal cellular processes and promote neuronal
loss.
6. Parkinson's disease and synucleinopathies
The focus on sumoylation has been predominantly with
respect to events in the nucleus which prompted investigation
into disorders involving intranuclear accumulation of protein
aggregates, such as NIID and polyglutamine diseases. With the
introduction of proteomic approaches, a significant number of
cytoplasmic SUMO targets have been identified, suggesting
that the effects of sumoylation may be more far reaching than
previously considered [43,44]. This has also proven to be the
case for neurological diseases involving misfolded cytosolic
proteins.Synucleinopathies are a group of neurodegenerative diseases
characterized by the accumulation of filamentous aggregates of
α-synuclein in cytoplasmic inclusion bodies and include
disorders such as Parkinson's disease, dementia with Lewy
bodies (DLB) and multiple system atrophy (MSA). SUMO1
immunoreactivity has been reported in MSA oligodendroglial
cytoplasmic inclusions as well as punctuated staining at the
nuclear membrane level [91]. Similar to other neurodegenera-
tive disorders, the colocalization of SUMO with cytosolic
inclusions raised the question of the identity of SUMO targets
within the aggregates. It has recently been reported that α-
synuclein is a substrate for SUMO1 providing a direct link with
these deposits [16] (Table 1).
Parkinson's disease (PD) is the most common movement
disorder that is characterized by progressive and extensive
loss of dopaminergic neurons and the accumulation of Lewy
bodies. Several genes involved in the pathogenesis of PD,
including α-synuclein and UCH-L1, are closely linked to the
ubiquitin–proteasome system (for review see [60]). Parkin is
an ubiquitin E3 ligase and mutations in this protein cause the
majority of familial PD cases. As another example of the
cross-talk between ubiquitin and SUMO pathways, it has been
shown that parkin regulates the turnover of the SUMO E3
ligase RanBP2 by catalyzing its ubiquitination and promoting
proteasome degradation [92]. More recently, a functional non-
covalent interaction between parkin and SUMO1 has been
reported in neuronal cells as well as in rat brain cortex [47],
which resulted in parkin nuclear localization and auto-
ubiquitination. This report further supports the importance
of conjugation-independent functions of SUMO and could
suggest a non-covalent role for the ubiquitin-like protein in
PD pathogenesis.
DJ-1 is a multifunctional protein involved in the transcrip-
tional regulation of genes [93]. It also plays a role in the
cellular response to oxidative stress [94], a known contributing
factor to dopaminergic neuron degeneration in PD (for review,
see [95]). Loss-of-function DJ-1, either by deletion or point
mutation, leads to early onset PD. With regard to sumoylation
pathway, DJ-1 is modified by SUMO1 [96] and also interacts
with members of the PIAS family [93], which act as SUMO
E3 ligases [20,21] (Table 1). Substitution of the DJ-1 SUMO
acceptor lysine, K130, abolishes its activity but does not affect
subcellular localization. It has been shown that the PD-related
DJ-1 missense mutant, L166P, can be mis-sumoylated as
compared to its wildtype counterpart. This was evident by the
presence of higher molecular weight SUMO/DJ-1-positive
bands and suggested that the mutant protein may have been
polysumoylated on selected lysine residues or sumoylated on
multiple target residues (Fig. 4A). Alternatively, SUMO
conjugation of the L166P may promote aggregation leading
to these high molecular weight species. These changes in
sumoylation of the L166P mutant can potentially explain its
insolubility, change in subcellular localization and instability,
which may be due to its rapid degradation by the proteasome
[96].
The DJ-1 L166P mutant and to a lesser extent the SUMO
site K130R mutant were more sensitive to oxidative stress
Fig. 4. SUMO affects on DJ-1 and its relationship to oxidative stress.
Parkinson's disease DJ-1 L166P mutant is incorrectly modified by SUMO,
leading to either polysumoylation or multisumoylation. This results in decreased
solubility, change in subcellular localization and increased proteasome
degradation of the DJ-1 mutant. These defects interfere with DJ-1 function
and lead to cellular sensitivity to oxidative stress.
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the DJ-1-mediated response to the cell insult ([96]). However,
the relationship between SUMO, DJ-1 and oxidative stress
appears to be increasingly complex. Initial reports demon-
strated that high oxidative stress upregulated sumoylation
[19,28]. However, subsequent investigations showed that high
but physiological concentrations of reactive oxygen species
(ROS) had the opposite effect. Under mild oxidative con-
ditions, SUMO E1 and E2 enzymatic activities are reversibly
inhibited by the formation of a disulfide bond between their
catalytic cysteines, which results in a downregulation of
SUMO conjugation [28]. The emerging picture could be one
of an integrated positive feedback pathway where both DJ-1
and SUMO are involved in the cellular response to oxidative
stress (Fig. 4B). That is, DJ-1 expression is regulated by
oxidation levels [96] and is also functionally dependent upon
sumoylation. SUMO activity and conjugation is in turn
regulated by the cellular redox status. How these pathways
are integrated in individual neurons, in the context of healthy
versus neurodegenerative brains, is an intriguing issue. One
could hypothesize that misregulation of the SUMO pathway
could result in DJ-1 loss of function that contributes to
decreased survival of sensitive neurons in Parkinson's
disease. DJ-1 is also associated with other neurodegeneration
in Pick's disease, MSA and frontotemporal dementia and
parkinsonism linked to chromosome 17 (FTDP-17) [97,98].
Therefore it is conceivable that the combination of the
sumoylation and DJ-1 pathways may also play a role in these
related diseases.7. Novel SUMO targets and other neurological disorders
Alzheimer's disease (AD) is the most common cause of
dementia in the elderly and is associated with cognitive and
memory dysfunction. This progressive disease is neuropatho-
logically characterized by the presence of senile plaques and
neurofibrillary tangles (NFT). Senile plaques result from the
extracellular accumulation of aggregated amyloid-beta (Aβ)
peptides, which are generated by β- (BACE) and γ-secretase
cleavage of the transmembrane amyloid precursor protein
(APP) (for review, see [99]). An in vitro expression and
sumoylation approach has identified APP as a SUMO1 target
[14]. In addition, an unbiased screening of a human brain cDNA
library has led to the identification of SUMO3 as a new
regulator of Aβ generation [100]. The study showed that
SUMO3 overexpression reduced Aβ production whereas
expression of SUMO mutants that cannot be conjugated or
form polymeric chains increased the production of these
amyloidogenic peptides. In contrast, a more recent study
investigating the effect of overexpression of the three major
SUMO isoforms on the APP processing pathway showed that
SUMO3 increased the generation of Aβ [101]. This was
accompanied by a reduced APP turnover and an increase in
APP holoprotein, C-terminal fragments and BACE levels. In
agreement with the study by Li et al., conjugation- and
polymerization-deficient mutants also stimulated Aβ secretion.
This observation illustrates a new example of a biochemical
pathway regulated by SUMO independent of its conjugation to
target proteins.
AD is also characterized by the presence of neurofibrillary
tangles (NFT), which are intracellular aggregates of tau [102]
and strongly immunoreactive for ubiquitin [103,104]. Tau is a
phosphoprotein involved in the regulation of microtubule
stability and is responsible for axonal development. Tau
pathology is also associated with other neurological disorders
collectively called tauopathies, which include frontotemporal
dementia (FTD), Pick's disease (PiD), progressive supranuclear
palsy (PSP) and corticobasal degeneration (CBD). It has
recently been demonstrated that tau was covalently modified
by SUMO1, and to a lesser extent by SUMO2 and SUMO3 [16]
(Table 1). The major modification site, lysine K340, maps to the
microtubule-tubule binding domain.
Amyotrophic lateral sclerosis (ALS) affects motor neurons in
the spinal cord and the brain. A generalized weakness
accompanied by muscle atrophy and progressive paralysis are
among the symptoms experienced by patients. The disorder
occurs mostly sporadically, but it can also be inherited. Genetic
mutations in the gene encoding superoxide dismutase 1
(SOD1), an abundant copper/zinc-containing protein, account
for some cases of familial ALS cases (For review, see [105]).
This cytoplasmic metalloenzyme is an important cellular
antioxidant and plays a vital role in detoxifying cells during
oxidative stress. Several independent proteomic studies identi-
fied yeast SOD1 as being covalently modified by SUMO1
[43,52,106,107] on multiple lysines, under normal and stress
conditions [106]. Sumoylation of human SOD1 has also been
observed but, in contrast to yeast, only a single lysine was
Table 2
Putative SUMO substrates of interest in the brain
Substrate Function/Relevance (Pathology) Reference
Androgen receptor
(AR)





Precursor to Aβ (AD) [14]
E2-25K Ubiquitin E2 enzyme Interacts
with Huntingtin (HD)
[35]
Dynamin Endocytosis of APP (AD) [46]
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wild-type and ALS-related mutant SOD1 which resulted in
decreased turnover and enhanced aggregation. Inclusion bodies
could be detected in these cell culture models that colocalized
with SUMO1 which is consistent with the accumulation of the
modified SOD1.
Proteomic approaches have led to the identification of a
large number of SUMO substrates from yeast and mammalian
cells under a variety of conditions (Table 2). Although many
of these have yet to be validated in cellular models or in vivo,
further investigation of these candidate SUMO targets may
provide additional insights into the involvement of sumoyla-
tion in neurodegenerative diseases. For example, E2-25K is an
unusual ubiquitin conjugating enzyme that also functions as an
ubiquitin E3 ligase to produce diubiquitin and free poly-
ubiquitin chains [109]. E2-25K is a sumoylation target and
conjugation impairs the formation of ubiquitin thioester and,
consequently, the generation of free ubiquitin chains [35]. E2-
25K is also expressed at high levels in the brain and interacts
with huntintin (Htt). This interaction is independent of the
length of the polyQ stretch but requires an intact Htt N-Fig. 5. SUMO mechanisms potentially involved in neurodegeneration. (A) The mo
shaded area). Sumoylated substrates can sequester critical proteins (2). Both SUMO-
transcription, which can be detrimental to cells (3). (B) A competition between SU
turnover. Conversely, proteasome inhibitors stimulate SUMO conjugation and induc
response to protein aggregation in order to promote their degradation by proteasom
specialized domains, where both SUMO and ubiquitin pathways are integrated. (D)
SUMO modification is regulated by the redox status. Furthermore, there is also a crterminal domain [110] which contains the target lysines for
SUMO and ubiquitin conjugation [70]. Another target of
interest is dynamin, which interacts with SUMO1, Ubc9 and
PIAS1 through its GTPase effector domain. Dynamin is a key
element in the secretory pathway which has been associated,
for example, with APP processing in Alzheimer's disease
[111]. Although no sumoylated dynamin has been detected, it
has been shown that expression of SUMO1 or Ubc9 inhibited
lipid-dependent oligomerization and decreased dynamin-
mediated endocytosis of transferrin [46].
Molecular chaperones are essential components of the
protein quality control in cells. They play critical roles in the
folding of newly synthesized polypeptides and targeting of
misfolded proteins for proteasome-mediated degradation.
Chaperones are also involved in aggresome formation and are
associated with protein inclusions in neurodegenerative dis-
eases (for review, see [112]). The majority of proteomic studies
have identified molecular chaperones as SUMO substrates,
including HSP90 and HSP70 [15,43,52,106,113,114]. Sumoy-
lation could potentially affect chaperones activity, their
recruitment to specific subcellular localizations as well as
interactions with substrates or other components involved in
protein quality control. Finally, several yeast proteasome
subunits have been identified as SUMO substrates which raises
the possibility that sumoylation may participate in proteasome
organization or regulation [43,44,114]. Chaperones and the
proteasome are two important systems that have been closely
linked to neurodegenerative diseases and represent another
potential connection to the sumoylation pathway.
8. Conclusions and perspectives
Considerable progress has been made in the exciting and
rapidly growing SUMO field. SUMO immunoreactivity hasdification of a substrate by SUMO can affect its subcellular localization (1, to
mediated effects can contribute to the formation of inclusions and/or affect gene
MO and ubiquitin can antagonize proteasome degradation and affect protein
e the formation of SUMO-positive aggregates. (C) Nuclear bodies are formed in
es (4). Evidence suggest that SUMO actively targets affected proteins to these
Sumoylation is involved in the cellular response to oxidative stress. Conversely,
oss-talk between oxidative stress and the proteasome pathway (5).
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degenerative diseases characterized by intranuclear and/or
cytosolic protein aggregates and could potentially be involved
in neurodegeneration processes. The identity of SUMO-
modified proteins that accumulate within protein lesions is
progressively being revealed. The regulation of biochemical
pathways by SUMO independent of its conjugation is also an
emerging concept, which is relevant to neurodegenerative
disorders.
The findings to date highlight the potential roles for SUMO
in regulating protein transport, targeting proteins to subcellular
proteasome-mediated degradation sites or in cellular responses
to stresses such as proteasome impairment and oxidative stress
(Fig. 5). To better understand these functions and their
contributions to neurological diseases, it will be necessary to
dissociate SUMO from the primary events that trigger the
pathological cascade from the secondary events that maintain
the progression towards neurodegeneration. The temporal and
spatial regulation of sumoylation during the course of
neurodegeneration needs to be investigated for the different
SUMO isoforms. Animal models for many of these disorders
have been established and similar approaches in combination
with SUMO transgenics may lead to a better understanding of
the effect of sumoylation on the underlying disease pathways.
With its implications in the proteasome pathway, oxidative
stress, transcriptional regulation, nuclear transport and protein
shuttling, a number of possibilities present themselves for
SUMO to manifest itself in these neurological disorders. If
SUMO does not drive on the road of neurodegeneration, it is at
least an important passenger. Further understanding of the role
of SUMO in the biochemical pathways involved in neurode-
generative processes could ultimately lead to novel therapeutic
strategies. In this order, two hypothetical therapeutic scenarios
for intervention in the SUMO pathway can be envisaged.
First, there are cases in which sumoylation is beneficial.
These include the cellular response to stresses (e.g. in PD), the
transport of proteins to degradation sites such as nuclear bodies
(e.g. in NIID) and the function of specific proteins such as DJ-1
(in PD). In cell culture, only overexpression of SUMO or
exposure to certain stress has been shown to upregulate
sumoylation. Chemical or biochemical activators of the
SUMO pathway are currently inexistent.
On the other hand, sumoylation may have detrimental
effects. This can be exemplified by a SUMO-induced increase
in toxic soluble oligomers (e.g. in HD and AD) or by
antagonizing proteasome-mediated degradation (e.g. in
DRPLA). Although proteasome inhibitors are available and in
clinical trials for a growing list of cancers, such chemical tools
are not yet available for the sumoylation pathway. SUMO
knockdown using an RNA interference approach has been
successfully performed in cell culture [101]. Expression of the
viral protein Gam1 has also been reported to downregulate
sumoylation [36] and could help to the design of pharmaceutical
reagents.
In any case, it must be taken into account that in contrast to
the ubiquitin–proteasome system, the sumoylation pathway
utilizes a single SUMO E1, E2 and only a few E3 enzymes.Consequently, any intervention in this pathway would affect a
wide variety of biochemical processes with various conse-
quences. The identification of regulators specific to a given
substrate will be needed to achieve specific therapeutic
interventions. Based on the rate of progress in the SUMO
field, many exciting and intriguing findings are to be expected
in the near future.
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